{{Drugbox
| IUPAC_name = 5-[(1''Z'')-''N''-(2-aminoethoxy)hexanimidoyl]-2-methylaniline
| image = Caproxamine.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 24047-16-3
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 9578268
| ChEMBL = 2106193
| ChemSpiderID = 7852632
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7YQT311430

<!--Chemical data-->
| C=15 | H=25 | N=3 | O=1 
| molecular_weight = 263.38 g/mol
| smiles = O(\N=C(/c1cc(N)c(cc1)C)CCCCC)CCN
}}

'''Caproxamine''' is a [[drug]] which was patented as an [[antidepressant]].<ref name="isbn0-412-46630-9">{{cite book | author = David J. Triggle | title = Dictionary of pharmacological agents | publisher = Chapman & Hall | location = London | year = 1997 | pages = | isbn = 0-412-46630-9 | oclc = | doi = | accessdate = }}</ref>

== References ==
{{Reflist}}


{{Antidepressants}}

[[Category:Amines]]
[[Category:Antidepressants]]
[[Category:Oximes]]


{{nervous-system-drug-stub}}